Talk:BeiGene

Intro and History sections

Thanks in advance for helping me out with this edit request to the Introduction and History sections of the article.

1. Please add the word "global" to the first sentence so that it reads: "BeiGene is a global biotechnology company…"
2. There is no reliable source that supports the claim in the second sentence of the Intro that the company was founded in Beijing. Please remove the words "in Beijing" from that sentence so it says instead: "Founded in 2010 by Xiaodong Wang…"
3. Also in the second sentence, but at the end, there is a list of office locations. For consistency, please remove the countries listed and switch them out for continents, so instead the list says: "…the company has offices in Asia, North America, Australia and Europe."
4. Please remove the last part of the last sentence. That clause is too much detail for the introduction, and is already stated in the "Research and development section." The part to be removed is "a Bruton's tyrosine kinase inhibitor that became the first cancer drug developed in China to gain the U.S. Food and Drug Administration's approval when it received accelerated approval to treat mantle cell lymphoma in November 2019."
5. In the History section, after the first sentence, please add the following sentence and source:

As of early 2023, the company had more than 9,000 employees worldwide.

References

Thanks again for all your help, LexBGNE (talk) 20:15, 28 February 2023 (UTC)

Done. Spotted your request on Athel cb's talk page. U003F^? 06:51, 5 May 2023 (UTC)

U003F, thank you for your help! LexBGNE (talk) 18:30, 11 May 2023 (UTC)

COI edit requests

Hi! BeiGene is a client of my employer, Porter Novelli. Requesting some updates to this article. I've also mocked up the changes here.

• I noticed this article has recently been moved from BeiGene, and all inline mentions of the company name updated. Per MOS:CAMELCASE, I suggest that this change be reverted, given that the vast majority of media coverage capitalizes the G in the name.
• Once the below has been reviewed, I'd love to revisit what else might be necessary to address the {{advert}} flag on this article.
• Update the {{Short description}} to "Global biotechnology company", per the article lead.

History

• Update, per the cited source:

As of early 2023, the company had more than 9,000 employees worldwide.

to

As of early 2023, the company had more than 9,400 employees worldwide.

• Delete

While many pharmaceutical drugs are manufactured in China, almost all early research and development for the drugs takes place elsewhere.

The closest citations in the text are and , but neither ref substantiates the information.

• Update with more neutral/condensed language:

Wang and Oyler envisioned a biopharmaceutical company with strong ties to China to conduct research and development. They chose to focus specifically on cancer treatment.

to

Wang and Oyler envisioned a biopharmaceutical company with research and development in China, focusing on cancer treatment.

• Update per the cited source:

By July 2011, they had recruited more than 60 Chinese scientists, including 20 who were U.S.-educated.

to

By July 2011, they had recruited 60 scientists, including 20 who were Chinese-born and U.S.-educated or had worked at an American or European pharmaceutical company.

• Update

In the US, Beigene has offices in California, Massachusetts, and New Jersey.

to

In the U.S., BeiGene has offices in California, Maryland, Massachusetts, and New Jersey.

• Add to end of section:

In November 2018, BeiGene began a license and collaboration agreement with biotech company Zymeworks. In December 2021, the two companies began a phase 3 clinical trial of zanidatamab, a bispecific antibody.

In November 2022, the company began offering a program to help patients better manage mental health issues associated with cancer, called "Talk About It". BeiGene also partnered with the Cancer Support Community to conduct additional research on cancer and mental health.

Research and development

• Delete

In addition to clinical research, BeiGene's early business model involved obtaining the rights to experimental medicines shelved by other pharmaceutical companies and taking them through early clinical trials at Chinese medical schools and hospitals. Successful formulas would either be sold to or co-developed with larger drugmakers who could fund the late-stage trials.

The cited source states this speculatively: "BeiGene hopes to buy..."; "Those that are successful may be sold back". Per WP:CRYSTALBALL, I believe it makes sense to remove this.

• Break this section into two subsections: "Tislelizumab" (the second paragraph, now the first if the above is implemented) and "Zanubrutinib" (currently the final paragraph).
• Delete "in both directions" – feels like odd wording.
• A couple tense/framing updates in the second paragraph to reflect the drug's current status:
  • Update "One of BeiGene's late-stage therapies" to "One of BeiGene's internally developed medicines"
  • Update "Tislelizumab is being developed as a monotherapy and in combination" to "Tislelizumab was developed as a monotherapy and for use in combination"
• Add (CLL) after the first mention of chronic lymphocytic leukemia and (SLL) after the first mention of small lymphocytic lymphoma.
• Add to end of third paragraph:

Zanubrutinib was approved for treatment of adult patients with CLL and SLL by the European Commission in November 2022 and by the FDA in January 2023.

• Add new subsection:

=== Pamiparib ===

Pamiparib (Partruvix) is a selective poly (ADP-ribose) polymerase 1 and 2 (PARP1 and PARP2) inhibitor developed by BeiGene. It has been approved in China for the treatment of BRCA recurrent advanced ovarian, fallopian tube or primary peritoneal cancer.

Sources

Thank you for your time and feedback! Mary Gaulke (talk) 19:30, 12 July 2023 (UTC)

WP:CRYSTAL pertains to text in Wikipedia, not to how text is worded in sources. Also, please provide the WikiLinks for Tislelizumab, Pamiparib, CLL and SLL so that they may be incorporated into the article. The term "in both directions", it's not clear from your request where this is located in the article. Please advise. Regards  Spintendo  15:29, 13 July 2023 (UTC)

Thanks for the quick reply! Pamiparib redirects to PARP_inhibitor#Examples_of_clinical_trials, so I think the wikilink later in that sentence may suit better. Here is a link for chronic lymphocytic leukemia; small lymphocytic lymphoma redirects to the same. Looks like the "in both directions" phrase was deleted from the article recently – I'll strike it out above. Thanks again. Mary Gaulke (talk) 22:07, 13 July 2023 (UTC)

Reply 13-JUL-2023

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request.  Spintendo  23:17, 13 July 2023 (UTC)

Edit request review 13-JUL-2023

As of early 2023, the company had more than 9,400 employees worldwide.  Approved. While many pharmaceutical drugs are manufactured in China, almost all early research and development for the drugs takes place elsewhere. Clarification needed. Wang and Oyler envisioned a biopharmaceutical company with research and development in China, focusing on cancer treatment.  Approved. By July 2011, they had recruited 60 scientists, including 20 who were Chinese-born and U.S.-educated or had worked at an American or European pharmaceutical company.  Declined. In the U.S., BeiGene has offices in California, Maryland, Massachusetts, and New Jersey  Declined. In November 2018, BeiGene began a license and collaboration agreement with biotech company Zymeworks. In December 2021, the two companies began a phase 3 clinical trial of zanidatamab, a bispecific antibody. Clarification needed. In November 2022, the company began offering a program to help patients better manage mental health issues associated with cancer, called "Talk About It". BeiGene also partnered with the Cancer Support Community to conduct additional research on cancer and mental health.  Declined. Update "One of BeiGene's late-stage therapies" to "One of BeiGene's internally developed medicines"  Approved. "Tislelizumab was developed as a monotherapy and for use in combination"  Approved. Add to end of third paragraph: Zanubrutinib was approved for treatment of adult patients with CLL and SLL by the European Commission in November 2022 and by the FDA in January 2023. Clarification needed. Pamiparib (Partruvix) is a selective poly (ADP-ribose) polymerase 1 and 2 (PARP1 and PARP2) inhibitor developed by BeiGene. It has been approved in China for the treatment of BRCA recurrent advanced ovarian, fallopian tube or primary peritoneal cancer.  Declined. ___________

Thank you as always for your feedback! A few specific responses:

• Note 2: The references in question do not need to be removed; they're substantiating the following sentence, "Wang and Oyler envisioned a biopharmaceutical company with research and development in China, focusing on cancer treatment."
• Note 3: Understood, but this request was to update content already in the article ("By July 2011, they had recruited more than 60 Chinese scientists, including 20 who were U.S.-educated."). If it's out of scope, do we want to delete it rather than updating it?
• Note 5: Updated with more specific wording:

In November 2018, BeiGene began a license and collaboration agreement with biotech company Zymeworks, giving BeiGene the rights to two drugs in certain markets and allowing BeiGene and Zymeworks to share research and development data. In December 2021, the two companies began a phase 3 clinical trial of zanidatamab, a bispecific antibody.

• Note 7: This is for the third paragraph of the "Research and development" section, at the end of the paragraph on zanubrutinib.
• Finally, any thoughts on my request to capitalize the G in the article title and throughout the body, per the majority of media coverage and MOS:CAMELCASE?

Sources

Thanks again. Mary Gaulke (talk) 21:02, 18 July 2023 (UTC)

Hi @Spintendo:! I neglected to ping you on the above so doing so now. Thank you! Mary Gaulke (talk) 13:56, 25 July 2023 (UTC)

Thank you for your reply.

1. The references in question do not need to be removed; they're substantiating the following sentence If the references do not need to be removed because they are already substantiating a nearby claim (and by "nearby" you mean WP:INTEGRITY is being followed) then no change needs to be made (because they're already properly substantiating that claim). If they are improperly substantiating a nearby claim because integrity is not being followed, then that needs to be specified in the request along with information on where to move the old/new references so that they substantiate the right claims. If the references are updating older references which are no longer correct, then the older references need to be included in the request so that they can be identified and removed from the article.
2. If it's out of scope, do we want to delete it rather than updating it? That's the goal, but that deletion should ideally come in the form of a new request.
3. at the end of the paragraph on zanubrutinib Is zanubrutinib Wikilinked? If the information is about the drug, then it should be placed on the drug's page and not on the page about the company.
4. Updated with more specific wording: In November 2018, BeiGene began a license and collaboration agreement with biotech company Zymeworks "Collaboration agreements" could mean anything, and beyond that seems to be just everyday information about the company's actions that is not really relevant to the article. If the company comes to an agreement with a certain phone service provider to handle its telephone calls or if the company enters into an agreement with a janitorial service to handle the cleaning of its buildings, those agreements, though extreme as examples, are just normal collaboration agreements that keep the company in business. If 10 years from now that collaboration agreement ended up producing a blockbuster drug which made major news around the world, then it would be relevant to include the information about that collaboration agreement in the article at that time. Regards,  Spintendo  05:08, 5 August 2023 (UTC)

@Spintendo: Hello!

1. To be clear, I'm requesting that

While many pharmaceutical drugs are manufactured in China, almost all early research and development for the drugs takes place elsewhere. Wang and Oyler envisioned a biopharmaceutical company with research and development in China, focusing on cancer treatment.

be updated to

Wang and Oyler envisioned a biopharmaceutical company with research and development in China, focusing on cancer treatment.

The sources verify the second sentence, but not the first. Hence, I believe it makes sense to delete the first sentence while retaining the second sentence and its sources.

Sources

All the rest makes sense, and I can open up a new request for item 2. I'd also welcome any feedback you have on how I can address the {{Advert}} tag and the {{Excessive citations}} tag you placed. Is the latter as simple as reviewing any locations where there are three citations and choosing one to remove? Thanks! Mary Gaulke (talk) 19:14, 7 August 2023 (UTC)

@MaryGaulke Thank you for your reply. The way you explained the first claim, about the drugs being manufactured in China, that makes much more sense now. I can remove the first part of those sentence. As far as the too many citations maintenance template, ideally, if one reference can cover a claim, then additional references are not necessary. The article should be combed to make sure that there are no duplicate references, meaning, there should not be two different sources confirming the exact same information. (I count 14 instances where two or more references stand side by side in the article, apparently referencing the same information. These should be checked to make sure they're not actually referencing different parts of the same sentence or sentences, in which case they should be moved to their proper positions.) I can't speak to the advert maintenance template, since I had nothing to do with its emplacement. Regards,  Spintendo  19:18, 15 August 2023 (UTC) and inserted text 20:02, 15 August 2023 (UTC)

Sounds great. Thanks for your help! Mary Gaulke (talk) 19:34, 15 August 2023 (UTC)

I would add that I typically ask COI editors to speak with the editor who placed the template to see if it can be removed, and if they don't receive a response then I'll take a look at it. Regards,  Spintendo  19:39, 15 August 2023 (UTC)

Roger that! I've reached out to the editor who placed the template. Thanks again. Mary Gaulke (talk) 19:49, 15 August 2023 (UTC)

Hi! Confirming it's been a week since I reached out to the editor who placed the template. While the editor has been active during that time, they have not replied to me, so I'm guessing they no longer wish to be involved. Any feedback you could share on addressing the advert flag would be most appreciated. Mary Gaulke (talk) 15:12, 22 August 2023 (UTC)

COI edit requests v.2

Hi again! As noted above, I'm a COI editor for BeiGene, opening up a new request for a few outstanding/new items per the discussion above.

1. Update the {{Short description}} to "Global biotechnology company", per the article lead.

2. In the infobox, please update the number of employees to 10,000

3. In the second paragraph of "History", delete per the above discussion:

By July 2011, they had recruited more than 60 Chinese scientists, including 20 who were U.S.-educated.

Alternatively, this could be updated as follows, per the cited source:

By July 2011, they had recruited 60 scientists, including 20 who were Chinese-born and U.S.-educated or had worked at an American or European pharmaceutical company.

4. To address {{excessive citations}}:

• Delete the second ref after "Wang and Oyler envisioned a biopharmaceutical company focusing on cancer treatment, with research and development both taking place in China." – The first ref is sufficient to confirm the information.
• Delete the first ref after "In a March 2018 follow-on offering, BeiGene raised another $758 million." – The second ref confirms the information.
• Delete the second ref after "In August 2018, the company had another IPO when it offered a secondary listing of its shares on the Hong Kong Stock Exchange, raising $903 million in the process."
• Update

In July 2017, BeiGene entered into a partnership with Celgene to continue the development and commercialization of the cancer drug BGB-A317, also known as tislelizumab.

to

In July 2017, BeiGene entered into a partnership with Celgene to continue the development and commercialization of the cancer drug BGB-A317, also known as tislelizumab.

• After "BeiGene also acquired Celgene's operations in China as well as the rights to commercialize Abraxane, Revlimid and Vidaza, Celgene's approved drugs in China.", add this ref: (This is actually a sentence that was missing a ref, so I found one.)
• Delete the first ref after "As part of the deal, Celgene made a $150 million equity investment in BeiGene and acquired the rights for the sale of tislelizumab overseas for $263 million, with another $980 million plus royalties contingent on future sales."
• Delete the second and third refs after "In 2019, Amgen Inc. acquired 20.5% of BeiGene in a deal valued at $2.7 billion, and gained a seat on BeiGene's board of directors. In turn, BeiGene acquired the rights to commercialize three Amgen pharmaceuticals, Xgeva, Kyprolis, and Blincyto, as well as 20 others in development, investing $1.25 billion toward their research."
• Delete the second ref after "In January 2021, BeiGene announced a collaboration and license agreement with Novartis to develop and commercialize tislelizumab in Canada, member countries of the European Union, Switzerland, Iceland, Japan, Liechtenstein, Mexico, Norway, Russia, United Kingdom, and the U.S."
• Delete the second ref after "In May 2021, BeiGene and Asieris Pharmaceuticals worked together to assess the efficacy and quality of Asieris's MetAP2 inhibitor and BeiGene's PD-L1 inhibitor for bladder cancer patients."
• Delete the first and second refs after "Tislelizumab is being developed as a monotherapy and for use in combination with other therapies for several types of cancer."
• Delete the second ref after "In September 2021, the U.S. Food and Drug Administration (FDA) accepted a biologics license application for tislelizumab to treat unresectable, recurrent locally advanced or metastatic esophageal squamous cell carcinoma that has previously been treated with systemic therapy."
• Delete the second ref after "BeiGene also developed zanubrutinib, a Bruton's tyrosine kinase inhibitor for the treatment of cancer, from a formula its scientists created in Beijing in 2012."
• Update

In November 2019, zanubrutinib became the first cancer drug developed in China to gain FDA approval; it received accelerated approval for the treatment of mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.

to

In November 2019, zanubrutinib became the first cancer drug developed in China to gain FDA approval; it received accelerated approval for the treatment of mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.

• Delete the first ref after "In September 2021, the FDA approved zanubrutinib to treat adults with Waldenström's macroglobulinemia, a rare non-Hodgkin lymphoma,"
• Delete the first ref after "and separately granted an accelerated approval for use of the drug in the treatment of relapsed or refractory marginal zone B-cell lymphoma in patients who have been treated with an anti-CD20 regimen."

Sources

Thank you for your time and support! Mary Gaulke (talk) 17:06, 16 August 2023 (UTC)

Approved and implemented.  Spintendo  17:51, 17 August 2023 (UTC)

COI edit requests for lead, History, Research and development

Hi! As noted above, I'm a COI editor for BeiGene. I'm hoping to build out this article a little more to reflect the structure and depth of information in comparable articles like Vertex Pharmaceuticals, BioNTech, and Biogen. Here's what I suggest:

• In the lead, update

including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

to

including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor.

For the symmetry of providing a brief description of each, rather than only tislelizumab.

• Add to end of "History":

As of 2023, the company was constructing a $700 million investment site for biologics manufacturing and research and development. Located in Hopewell, New Jersey, it is scheduled to open in 2024.

• I think it makes sense to move the last two paragraphs of "Research and development" into a new "Products" or "Medicines" section. Each paragraph could also be a subsection: "Tislelizumab" and "Zanubrutinib".
• In the paragraph on zanubrutinib, update

In June 2020, the drug was also approved in China for the treatment of MCL, chronic lymphocytic leukemia, and small lymphocytic lymphoma.

to

In June 2020, the drug was also approved in China for the treatment of MCL, chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL); it was then approved for the treatment of CLL and SLL by the European Commission in November 2022 and by the FDA in January 2023.

N.B. This is similar to a request I previously proposed that was rejected above. I've adjusted the request to appear adjacent to related information in the article (the Chinese approval of the drug for the same indications). If this information is not appropriate for this article, I suggest the sentence be removed entirely; listing only the Chinese approval when it is also approved in the US and EU seems unnecessarily confusing.

• Add to the end of "Research and development":

From 2019 to 2022, BeiGene's internal research team of preclinical scientists grew from 200 to more than 800 people. In 2022, BeiGene became the only pharmaceutical company in China to have invested more than 10 billion yuan ($145 billion) in research and development. As of 2023, the company had approximately 50 clinical candidates or products in development or in the commercialization process.

Sources

Thank you for your time and feedback! Mary Gaulke (talk) 19:00, 11 September 2023 (UTC)

Reply 12-SEP-2023

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request.  Spintendo  00:46, 13 September 2023 (UTC)

Edit request review 12-SEP-2023

including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor.  Approved. As of 2023, the company was constructing a $700 million investment site for biologics manufacturing and research and development. Located in Hopewell, New Jersey, it is scheduled to open in 2024.  Declined. In June 2020, the drug was also approved in China for the treatment of MCL, chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL); it was then approved for the treatment of CLL and SLL by the European Commission in November 2022 and by the FDA in January 2023. Clarification needed. From 2019 to 2022, BeiGene's internal research team of preclinical scientists grew from 200 to more than 800 people. In 2022, BeiGene became the only pharmaceutical company in China to have invested more than 10 billion yuan ($145 billion) in research and development. As of 2023, the company had approximately 50 clinical candidates or products in development or in the commercialization process.  Declined. ___________

revised COI edit requests for lead, History, Research and development

Hello! Sharing revised versions of my edit requests above per the feedback received.

• Add to end of "History":

As of 2023, the company was constructing a $700 million investment site in Hopewell, New Jersey, for biologics manufacturing and research and development.

• Split the last two paragraphs of "Research and development" into a new section titled "Medicines" or "Products".
• In the paragraph on zanubrutinib (currently in "Research and development"), update

In June 2020, the drug was also approved in China for the treatment of MCL, chronic lymphocytic leukemia, and small lymphocytic lymphoma.

to

In June 2020, the drug was also approved in China for the treatment of MCL, chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL); it was then approved for the treatment of CLL and SLL by the European Commission in November 2022 and by the FDA for the same indications in January 2023.

References

Thanks for your time! Mary Gaulke (talk) 13:55, 18 October 2023 (UTC)

Reply 18-OCT-2023

  Edit request partially implemented  

1. N The information concerning the Hopewell site was not added, for the same reason given in the reply from 12-SEP-2023 (i.e., the company was constructing as opposed to constructed meaning finished).
2. Y The paragraph on zanubrutinib was updated.
3. N The last two paragraphs were not split under a new heading because the suggested level of that heading (i.e., 2 or 3) was not provided with the request.

Regards,  Spintendo  02:18, 19 October 2023 (UTC)

Nov. 2023 COI edit request

Hi! COI editor for BeiGene here with a few new requests.

• In the final paragraph of "History", add before "In May 2021,":

Novartis returned the rights to tislelizumab to BeiGene in September 2023.

(I'm suggesting this placement as it follows a previous sentence on the Novartis agreement.)

• Split the last two paragraphs of "Research and development" into a new level-2 section titled "Medicines" or "Products".
• Add after the first paragraph of "Research and development":

In the years since, BeiGene has shifted toward an integrated approach to research and development, investing in in-house clinical development and trials rather than partnering with contract research organizations to run trials. The company has built up the capacity to run clinical trials in several regions simultaneously, providing larger numbers of patients with more diversity. According to BeiGene, this approach has reduced trial costs by 30% and reduced the time trials take. As of 2022, BeiGene had trial sites in 45 countries.

BeiGene has favored head-to-head clinical trials to validate the benefits of medicines, including two large global phase 3 clinical trials comparing zanubrutinib to ibrutinib between 2017 and 2023. In 2022, BeiGene became the only pharmaceutical company in China to have invested more than 10 billion yuan ($145 billion) in research and development.

• Finally, could the {{advert}} flag be removed from this article? I reached out to the editor who placed the template a few months ago for feedback on how to address it and haven't heard back. I also welcome any feedback on how I can help with addressing the advert flag.

References

Thank you for your help! Mary Gaulke (talk) 21:38, 30 November 2023 (UTC)

Reply 30-NOV-2023

  Edit request partially implemented  

1. Y The information regarding Novartis was added.
2. N The information regarding contract research organizations was not added, because other information in the article already covers this change in business models (In addition to clinical research, BeiGene's early business model involved obtaining the rights to experimental medicines shelved by other pharmaceutical companies and taking them through early clinical trials at Chinese medical schools and hospitals. Successful formulas would either be sold to or co-developed with larger drugmakers who could fund the late-stage trials.
3. N The infomration regarding Beigene's reduction in trial costs was not added. It is not Wikipedia's duty to tell the world that Beigene is saving money.
4. N The information concerning the phase 3 trials was not added, as what Beigene favors or does not favor is not Wikipedia's concern. Additionally, the claim of being the "only pharmaceutical company" cannot be substantiated with only one provided reference.

• Please provide diffs of your efforts to reach out to the editor who posted the maintenance message.

Regards,  Spintendo  03:29, 1 December 2023 (UTC)

@Spintendo: Hi! Here's the diff where I reached out to the editor who posted the maintenance message. Thanks! Mary Gaulke (talk) 22:42, 12 December 2023 (UTC)

Thank you for providing this. I've reached out to the editor as well. By the looks of their contributions, they are quite busy, so it's understandable if they were unable to get back to us. I reiterated that we value their input, and if they wished so in the future we would be happy to have them join in our discussion with any comments/concerns. In the meantime, I've removed the template, since we cannot know for certain if the conditions which they felt caused its placement are still in the article or have been resolved. Regards,  Spintendo  04:38, 14 December 2023 (UTC)

March 2024 COI edit requests

Hi! COI editor for BeiGene here again with a couple new requests:

• In infobox, update

| num_employees = 10,000

to

| num_employees = 10,600

| num_employees_year = 2024

• Add to end of "History":

In 2023, BeiGene saw a 75% increase in product sales to $2.2 billion, primarily due to sales of Brukinsa (zanubrutinib), which more than doubled 2022 sales and attained blockbuster drug status with $1.3 billion in sales.

References

Thanks for your help! Mary Gaulke (talk) 18:14, 5 March 2024 (UTC)

Hello there!

I'm happy to admit I'm a newer wiki editor! But, I have mostly been into IBX field stuff.

As such, I'm happy to add your proposed IBX changes via the citation.

"

| num_employees = 10,000

to

| num_employees = 10,600

| num_employees_year = 2024

However, I am not as yet well versed in the protocol for the actual article bodies and their cites/phrasings.

We all start somewhere, right, maybe? If you're happy to (not sure of that protocol here as well) possibly: re-request the latter half of your request for a more seasoned editor to review...

I also can't argue against it, so if my full-agreement, half-contribution is not helpful, please let me know!

I'll shut up.

I'm learning!

Thanks! Dunkinidaho (talk) 06:24, 24 March 2024 (UTC)

Hello there again, @MaryGaulke!

I've refreshed my article-body notability & RS chops... and as it turns out, I'd be happy to add your edit AS suggested, and (checking back here in a couple days) will proceed to do so-- barring no fellow editor pushback between.

Along with the IBX update for '24,I find it "well sourced*, neutral, and follows other Wikipedia guidelines and policies.

Thanks again,

d-id

(*I think the actual beigene-hosted SEC filing (cited specifically for the IBX info update) in tandem to the one you provided (and cited in the sentence added to "History") would speak to the verifiability of the claim in the cited RS, that itself cites the official fed filing. But I think if anything this is overkill, and just more links on wikipedia, actually?) Dunkinidaho (talk) 06:18, 25 March 2024 (UTC)

@Dunkinidaho: Thanks for your help! I believe the same re: the SEC filing – I believe primary source isn't necessary given the secondary source cites it. Mary Gaulke (talk) 20:14, 25 March 2024 (UTC)

Conflict of interest edits

I believe this article is being edited by editors who have a conflict of interest and/or are being paid. In particular, several new accounts have been created minutes before their first edit, and have made several edits to this article, and no other article. Seeing this talk page, this company obviously has a lot of interest in keeping this page how they want it, and so they put in a lot of COI edit requests. Unfortunately it seems some edits are happening that are not going through this proper channel. I'm going to post to the noticeboard if I get no response.

• Nyg58 (talk · contribs · deleted contribs · logs · filter log · block user · block log)
• Kablankblank (talk · contribs · deleted contribs · logs · filter log · block user · block log)
• Nkmillsmedia (talk · contribs · deleted contribs · logs · filter log · block user · block log)
• Mtpmedia (talk · contribs · deleted contribs · logs · filter log · block user · block log)
• Crileymiller (talk · contribs · deleted contribs · logs · filter log · block user · block log)
• UofMMedia (talk · contribs · deleted contribs · logs · filter log · block user · block log)

@Nyg58: @Kablankblank: @Nkmillsmedia: @Mtpmedia: @Crileymiller: @UofMMedia: Kimen8 (talk) 01:20, 28 March 2024 (UTC)

Several of these editors have received blocks due to their username violating the username policy. In particular, they are Groups that are being paid to edit this article. Since there are so many paid contributions in such a short span of time, I have annotated the article with appropriate templates. This is egregious. I want to expand the list to also include:

• Kyehyun Park (talk · contribs · deleted contribs · logs · filter log · block user · block log)
• Sjbmediaupdate (talk · contribs · deleted contribs · logs · filter log · block user · block log)
• Honeyboo2024 (talk · contribs · deleted contribs · logs · filter log · block user · block log)
• AFMRwesternsection (talk · contribs · deleted contribs · logs · filter log · block user · block log)
• Orthonews (talk · contribs · deleted contribs · logs · filter log · block user · block log)

I have created a post to the noticeboard here.

Kimen8 (talk) 13:46, 31 March 2024 (UTC)

@MaryGaulke: given your role as (appropriately; thank you) declared above, are you aware of this? Andy Mabbett (Pigsonthewing); Talk to Andy; Andy's edits 15:40, 31 March 2024 (UTC)

@Pigsonthewing: Hi! Unfortunately, Porter Novelli (my employer) is no longer representing BeiGene on Wikipedia. Happy to answer questions here or via email if WP:OUTING is a concern. I can confirm I advised my client on Wikipedia's COI disclosure policies. Mary Gaulke (talk) 16:30, 31 March 2024 (UTC)

Thank you; that's clear enough. Andy Mabbett (Pigsonthewing); Talk to Andy; Andy's edits 16:38, 31 March 2024 (UTC)

May 2024 COI edit requests

Hi, I'm working as a COI editor for BeiGene again, requesting some edits to this article:

• In the lead, update

BeiGene, Ltd. is a China-based drug developer.

to

BeiGene, Ltd. is a drug developer headquartered in Cambridge, Massachusetts, with major offices in Beijing and Basel.

Swapping in a more recent and accurate source.

• In the lead, update

BeiGene has a large presence in Chinese market.

to

BeiGene sells its products globally, with large presences in China, Europe and the U.S.

• Move the first paragraph of "Research and development" ("In addition to clinical research,...late-stage trials.") to follow the second paragraph of "History". I believe this makes more sense there since it's not focused on the company's current business model.
• Move

In September 2021, the U.S. Food and Drug Administration (FDA) accepted a biologics license application for tislelizumab to treat unresectable, recurrent locally advanced or metastatic esophageal squamous cell carcinoma that has previously been treated with systemic therapy.

from the end of the second paragraph of "Research and development" to the start of the fourth paragraph (before "As of 2023...") in order to put information in chronological order.

• Add to end of third paragraph of "Research and development" (after "...an anti-CD20 regimen."):

The FDA approved zanubrutinib plus obinutuzumab for the treatment of relapsed/refractory follicular lymphoma in March 2024.

• In "History", update

The company initially primarily operated in China.

to

The company initially had a presence in both the U.S. (Philadelphia) and China (Beijing).

• Move

In March 2024, tislelizumab (Tevimbra) received FDA approval for the treatment of advanced or metastic esophageal squamous cell carcinoma after prior chemotherapy. This FDA approval marked BeiGene's second for an internally developed medicine.

from the "History" section to the end of the second paragraph of "Research and development" (the one focused on tislelizumab). I also suggest updating to an external source and correcting the spelling of "metastatic", like so:

In March 2024, tislelizumab received FDA approval for the treatment of advanced or metastastic esophageal squamous cell carcinoma after prior chemotherapy. This FDA approval marked BeiGene's second for an internally developed medicine.

• Add to end of penultimate paragraph of "History":

BeiGene and the non-profit BeiGene Foundation partnered with the health equity non-profit Max Foundation in 2023 to make Brukinsa available for free to patients in 29 countries over the following three years.

Sources

Thanks for your time and consideration. Mary Gaulke (talk) 18:16, 21 May 2024 (UTC)

@MaryGaulke:, please clarify the nature of the representation relationship. You had said on March 31, 2024 that Porter Novelli is no longer representing BeiGene. I do see that request essentially challenges my recent edit and given the discussion that has taken place fairly recently and concerns raised in Wikipedia:Conflict_of_interest/Noticeboard/Archive_207#BeiGene about downplaying Chinese origin, this should be discussed to achieve consensus first.

Courtesy pings to @Kimen8 and Pigsonthewing: Graywalls (talk) 07:02, 2 June 2024 (UTC)

Hi – I’ve resumed working with BeiGene on the condition that BeiGene no longer edit this article directly. Happy to answer any questions about these requests. Mary Gaulke (talk) 14:13, 3 June 2024 (UTC)

Accuracy in Lede

I am the new COI editor for BeiGene; I joined the company in July 2024.

I am asking the community to revise the first sentence of the lede to remove the words "China-based" and read instead as "global".

The company has offices around the world, including in China, but it is not based there. Several sources can be used to substantiate this:

Forbes (July 2024) - "BeiGene was not incorporated in China and has never been headquartered in China...BeiGene has never had a formal headquarters in China or otherwise."

Forbes (August 2019)- "BeiGene is officially registered as a Cayman Islands company. It was established in Beijing and has since expanded its operations to the U.S. and Australia."

The Fast Company - "Headquartered in Cambridge, Massachusetts, with offices in Beijing and Basel, Switzerland..."

Life Science Leader - "BeiGene's CFO and strategy officer, along with the company's chief counsel, are in Boston. The company chief medical officers of IO and hematology are in Emeryville, CA and San Mateo, CA, respectively...BeiGene [doesn't] think of any one geographic area as being the company's control center."

This issue was addressed and resolved by U003F in May 2023, but has now been erroneously re-introduced. Could you please correct the current language? Thank you, SunshineWinter (talk) 13:01, 28 August 2024 (UTC)